Adrienne Weil
Nessuna posizione attualmente
Storia della carriera di Adrienne Weil
Precedenti posizioni note di Adrienne Weil
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Orrick, Herrington & Sutcliffe LLP
 Orrick, Herrington & Sutcliffe LLP Miscellaneous Commercial ServicesCommercial Services Orrick, Herrington & Sutcliffe LLP engages in the provision of legal services. Its practices include: antitrust and competition; banking and finance; capital markets; copyright, trademark and false advertising; cyber, privacy and data innovation; employment law and litigation; energy; financial services litigation; global compliance and regulatory, infrastructure; intellectual property; patents; public finance; real estate; securities litigation; supreme court and appellate; tax advocacy; technology transactions; trials; and white collar, investigations, securities litigation and compliance. The company was founded by John R. Garboe in 1863 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - | - |
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Consigliere Generale | - | - |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| General Counsel | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
Orrick, Herrington & Sutcliffe LLP
Orrick, Herrington & Sutcliffe LLP Miscellaneous Commercial ServicesCommercial Services Orrick, Herrington & Sutcliffe LLP engages in the provision of legal services. Its practices include: antitrust and competition; banking and finance; capital markets; copyright, trademark and false advertising; cyber, privacy and data innovation; employment law and litigation; energy; financial services litigation; global compliance and regulatory, infrastructure; intellectual property; patents; public finance; real estate; securities litigation; supreme court and appellate; tax advocacy; technology transactions; trials; and white collar, investigations, securities litigation and compliance. The company was founded by John R. Garboe in 1863 and is headquartered in San Francisco, CA. | Commercial Services |
- Borsa valori
- Insiders
- Adrienne Weil
- Esperienza
